Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis

Güler-Yüksel, Melek; Klarenbeek, Naomi B; Goekoop-Ruiterman, Yvonne PM; de Vries-Bouwstra, Jeska K; van der Kooij, Sjoerd M; Gerards, Andreas H; Ronday, H Karel; Huizinga, Tom WJ; Dijkmans, Ben AC; Allaart, Cornelia F; Lems, Willem F

doi:10.1186/ar3025

Table 1 Baseline demographic and disease characteristics from patients from the BeSt cohort who are included and not included in this study

From: Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis

Demographic variables	Patients included in study (n = 256)	Patients not included in study (n = 252)	Pvalue
Age, years^†	54 (14)	54 (13)	0.941
Women, %	65	70	0.208
Postmenopausal, %	66	68	0.817
Randomization between the treatment groups, %	Sequential monotherapy: 25 Step-up therapy: 23 Initial combi therapy with prednisone: 27 Initial combi therapy with infliximab: 26	Sequential monotherapy: 25 Step-up therapy: 25 Initial combi therapy with prednisone: 25 Initial combi therapy with infliximab: 25	0.921
Disease related variables
Symptom duration, weeks^‡	24 (14-53)	23 (13-53)	0.929
Disease duration, weeks^‡	2 (1-5)	3 (1-5)	0.011
ACPA positive, %, n = 247 (not all baseline)	54	70	0.000
RF positive, %	62	68	0.175
DAS^†	4.4 (0.9)	4.4 (0.9)	0.529
ESR^‡	37 (19-54)	36 (19-57)	0.781
CRP^‡	20 (9-58)	26 (10-55)	0.272
HAQ score, 0-3 scale^†	1.4 (0.6)	1.4 (0.7)	0.276
Total SHS, 0-448 scale^{‡, †} n = 248	5.9 (8.2)/2.5 (0.5-8.5)	8.7 (12.7)/4.3 (1.0-11.0)	0.024*
Erosion score, 0-280 scale^{‡, †}	2.8 (4.7)/1 (0.0-3.5)	3.9 (6.2)/1.5 (0.0-5.0)	0.011*
JSN score, 0-168 scale^{‡, †}	3.0 (4.8)/1.0 (0.0-4.1)	4.8 (7.7)/2.0 (0.0-5.6)	0.041*
Total SHS hands, 0-280 scale^{‡, †}	3.0 (4.8)/1.0 (0.0-3.5)	4.6 (8.4)/1.0 (0.0-5.0)	0.217*
Erosion score hands, 0-160 scale^{‡, †}	0.9 (1.8)/0.0 (0.0-1.0)	1.4 (3.1)/0.5 (0.0-1.0)	0.112*
JSN score hands, 0-120 scale^{‡, †}	2.1 (3.9)/0.0 (0.0-3.0)	3.1 (6.0)/0.50 (0.0-3.6)	0.247*
Total SHS feet, 0-168 scale^{‡, †}	2.8 (5.4)/0.5 (0.0-3.0)	4.1 (7.2)/1.5 (0.0-4.5)	0.011*
Erosion score feet, 0-120 scale^{‡, †}	1.9 (3.9)/0.5 (0.0-2.0)	2.5 (4.6)/0.5 (0.0-2.5)	0.123*
JSN score feet, 0-48 scale^{‡, †}	0.9 (2.0)/0.0 (0.0-1.0)	1.7 (3.4)/0.0 (0.0-2.0)	0.013*
Presence erosive damage ≥ 1 unit,	70	74	0.321
% n = 248	28	34	0.166
Presence erosive damage hands ≥ 1 unit, %	40	46	0.205
Presence erosive damage feet ≥ 1 unit, %
Hand BMD (g/cm²)^†	0.59 (0.08)	0.59 (0.09) n = 107	0.870

†Mean (standard deviation); ‡ median (interquartile range); * P values derived from non-parametric tests.
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS, Sharp-van der Heijde score.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us